Clinical Trial Update: Neoadjuvant Immunotherapy for Resectable Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant immunotherapy trial for resectable gastric cancer has completed, sponsored by Qilu Hospital of Shandong University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED